首页> 美国卫生研究院文献>The FASEB Journal >Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms
【2h】

Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms

机译:治疗21世纪的炎症和感染:解码解析介体和机制的新提示

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Practitioners of ancient societies from the time of Hippocrates and earlier recognized and treated the signs of inflammation, heat, redness, swelling, and pain with agents that block or inhibit proinflammatory chemical mediators. More selective drugs are available today, but this therapeutic concept has not changed. Because the acute inflammatory response is host protective to contain foreign invaders, much of today’s pharmacopeia can cause serious unwanted side effects, such as immune suppression. Uncontrolled inflammation is now considered pathophysiologic and is associated with many widely occurring diseases such as cardiovascular disease, neurodegenerative diseases, diabetes, obesity, and asthma, as well as classic inflammatory diseases (e.g., arthritis and periodontal diseases). The inflammatory response, when self-limited, produces a superfamily of chemical mediators that stimulate resolution of the response. Specialized proresolving mediators (SPMs), identified in recent years, are endogenous mediators that include the n-3–derived families resolvins, protectins, and maresins, as well as arachidonic acid–derived (n-6) lipoxins, which promote resolution of inflammation, clearance of microbes, reduction of pain, and promotion of tissue regeneration via novel mechanisms. Aspirin and statins have a positive impact on these resolution pathways, producing epimeric forms of specific SPMs, whereas other drugs can disrupt timely resolution. In this article, evidence from recent human and preclinical animal studies is reviewed, indicating that SPMs are physiologic mediators and pharmacologic agonists that stimulate resolution of inflammation and infection. The findings suggest that it is time to challenge current treatment practices—namely, using inhibitors and antagonists alone—and to develop immunoresolvents as agonists to test resolution pharmacology and their role in catabasis for their therapeutic potential.—Serhan, C. N. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.
机译:希波克拉底时期和更早时期的古代社会的从业者使用阻断或抑制促炎性化学介质的药物识别并治疗了炎症,高温,发红,肿胀和疼痛的迹象。今天有更多选择性药物可供使用,但是这种治疗概念并未改变。由于急性炎症反应可以阻止外来入侵者入侵,因此当今的大多数药典都可能导致严重的不良副作用,例如免疫抑制。现在认为不受控制的炎症是病理生理学的,并且与许多广泛存在的疾病如心血管疾病,神经退行性疾病,糖尿病,肥胖症和哮喘以及经典的炎症性疾病(例如关节炎和牙周疾病)有关。炎症反应自限时,会产生化学介体超家族,刺激反应的消退。近年来确定的专门的前分解介体(SPM)是内源性介体,包括n-3衍生的家族resolvins,protectins和maresins,以及花生四烯酸衍生的(n-6)脂类毒素,它们促进炎症的消退。 ,清除微生物,减轻疼痛和通过新机制促进组织再生。阿司匹林和他汀类药物对这些拆分途径具有积极影响,产生特定SPM的差向异构形式,而其他药物则可能破坏及时拆分。在本文中,回顾了来自最近的人类和临床前动物研究的证据,表明SPM是刺激炎症和感染消退的生理介质和药理激动剂。研究结果表明,是时候挑战当前的治疗方法了,即仅使用抑制剂和拮抗剂,并开发免疫溶剂作为激动剂,以测试解析药理学及其在宣泄中的作用,从而发挥其治疗潜力。 21世纪:解码分辨率介体和机制的新提示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号